# Effect of an Early Time Restricted Eating Mediterranean Diet Compared to Naltrexone/Bupropion on Liver Fibrosis in People With Cardiometabolic Risk Factors in a Hospital Outpatient Clinic (MEDFAST-study)

> **NCT06845345** · PHASE4 · ENROLLING_BY_INVITATION · sponsor: **Carmen Dietvorst** · enrollment: 70 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2
- Liver Fibrosis
- Liver Steatoses
- Hepatic Steatosis
- Hepatic Fibrosis
- Overweight or Obesity
- MASLD
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
- Cardio-metabolic Risk
- Cardio-metabolic Health
- Hypertension
- Dyslipidaemia

## Interventions

- **OTHER:** early time restricted Mediterranean diet
- **DRUG:** Mysimba

## Key facts

- **NCT ID:** NCT06845345
- **Lead sponsor:** Carmen Dietvorst
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-04-14
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06845345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06845345, "Effect of an Early Time Restricted Eating Mediterranean Diet Compared to Naltrexone/Bupropion on Liver Fibrosis in People With Cardiometabolic Risk Factors in a Hospital Outpatient Clinic (MEDFAST-study)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06845345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*